Full-Time

Business System Analyst

NAMSA

NAMSA

1,001-5,000 employees

Compensation Overview

$54.4k - $80k/yr

Irvine, CA, USA + 9 more

More locations: Germany | Toledo, OH, USA | Madrid, Spain | United Kingdom | Minneapolis, MN, USA | France | Atlanta, GA, USA | St Paul, MN, USA | United States

Hybrid

Category
IT & Security (1)
Required Skills
Agile
Software Testing
Visio
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Bachelor’s Degree in Computer Science, Information Technology, Business Administration or related discipline required. MBA or Advanced degree a plus.
  • 2-5 years’ experience in computer systems, business, analyst or related discipline preferred.
  • Proven experience in software development life cycle, including business process and requirements documentation, analysis, design, system construction, testing, training, communication planning and deployment (concept to deployment).
  • Proven experience configuring packaged, integrated systems.
  • Hands on experience in gathering, documenting, and communicating project business and application architecture requirements using Microsoft Word, PowerPoint, Excel, Visio, and other appropriate software.
  • Proven customer service/user support skills and experience in working with NAMSA business unit areas as well as in working with and directing vendor support personnel.
  • Ability to manage multiple tasks and manage small to large projects in a cross-functional, global environment.
  • Demonstrated experience in implementing and supporting integrated, enterprise 3rd party packaged software and cloud solutions.
  • Demonstrated working knowledge of systems supporting business processes.
  • Must have strong interpersonal skills, be self-motivated, have strong desire to learn, and be adaptable to a fast paced, ever-changing environment.
  • Operational and technical knowledge of the assigned business unit.
  • Understanding of both waterfall and agile project methods
Responsibilities
  • Develops Business analysis, design, configuration, coordination, implementation and support.
  • Develops specific system deployment activities that include the following: functional requirements definition, detailed technical design, system configuration, conversion and integration requirements, unit testing, systems test, acceptance test, go-live, and production turn over.
  • Participates in process improvements including, formulation and definition of technical scope and objectives of project, analysis of current business practices, processes, and systems, define detailed project tasks, and participating on a matrix team to execute projects.
  • Actively participates in enterprise-wide change management processes for requested system revisions.
  • Provides escalated technical support for enterprise client areas on existing business systems.
  • Tracks and addresses bugs identified in testing and production.
  • Conceptualizes new processes and systems that add value to NAMSA business units.
  • Provides user stories to multi-disciplinary teams and define the business-driven acceptance criteria.
  • Proactively engages technical Associates to schedule and execute required tasks.
  • Cultivates and maintains successful relationships between Information Technology team and Associates from various NAMSA organizations globally.
  • Documents system for turnover and training of NAMSA Associates, Information Technology peers, and Service Desk.
  • Performs other duties as assigned.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Toledo, Ohio

Founded

1967

Simplify Jobs

Simplify's Take

What believers are saying

  • Ophthalmic device market demands integrated solutions; partnership captures fragmented vendor consolidation opportunity.
  • Lexitas' 15-year ophthalmic track record and BCVA certification program strengthen trial execution quality.
  • Global reach across U.S., Europe, Asia-Pacific positions NAMSA for anterior/posterior segment cell/gene therapy trials.

What critics are saying

  • Integration failures from six acquisitions since 2021 disrupt operations and trigger client exodus.
  • Cultural misalignment between NAMSA's device focus and Lexitas' pharma-oriented model causes sponsor attrition.
  • FTC antitrust scrutiny targets NAMSA's biocompatibility dominance; divestitures dismantle end-to-end model.

What makes NAMSA unique

  • Unified ophthalmic platform embeds Lexitas' 700+ sites directly into NAMSA's device development infrastructure.
  • End-to-end lifecycle support from preclinical through commercialization under single contract and accountability.
  • Device-native expertise combines FDA endpoint fluency, IDE strategy, and ophthalmic clinical specialization.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at NAMSA who can refer or advise you

Benefits

Remote Work Options

Company News

PR Newswire
Mar 3rd, 2025
Namsa Completes Acquisition Of Wuxi Apptec Us Medical Device Testing Business

TOLEDO, Ohio, March 3, 2025 /PRNewswire/ -- NAMSA, a leading US based MedTech testing, clinical and regulatory consulting firm, announced that it finalized its acquisition of WuXi AppTec's US medical device testing operations on February 28.The acquisition brings together two of the most trusted names in medical device biological safety testing, serving more than 4,000 manufacturers worldwide.Lisa Olson, NAMSA Senior Vice President of Global Laboratory Services notes: "Together, we now have unmatched scientific expertise in biocompatibility, microbiology, preclinical and extractables and leachables testing. With the addition of WuXi AppTec medical device testing facilities in the US, we now have more scientists, more lab capacity and more expertise with a wider variety of medical devices than any other company. This combined expertise will continue to enable our work with clients to develop testing and consulting strategies tailored to their specific device and regulatory pathways."NAMSA has been expanding its reach in recent years as it continues to diversify its offering beyond biological safety testing. Since 2021, the company has acquired no fewer than six companies focused on preclinical or clinical research, making NAMSA one of the leading MedTech focused CROs. Brian Smith, NAMSA's recently appointed CEO noted: "This acquisition is part of our larger strategy to broaden our service offering and solidify our position as the go-to resource for manufacturers bringing new life-saving technologies to market while upholding the same high standards of client focused service you have come to expect from NAMSA."About NAMSAHelping medical device Sponsors improve healthcare since 1967, NAMSA is a leading global MedTech testing, clinical and regulatory consulting firm. With a deep pool of testing, clinical and regulatory experts, and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development

PR Newswire
Feb 24th, 2025
Brian P. Smith Joins Namsa As Chief Executive Officer; Brings 15+ Years Of Life Sciences Leadership Expertise To Role

TOLEDO, Ohio, Feb. 24, 2025 /PRNewswire/ -- NAMSA, a world-leading MedTech testing, clinical and regulatory consulting firm, announced today that Brian P. Smith has taken on the role of NAMSA's next Chief Executive Officer. Most recently, Brian served as the Chairman and Chief Executive Officer of Ad-Tech Medical Instrument Corp., a leading US neuro-diagnostic company.Andre-Michel Ballester, NAMSA's outgoing CEO, will transition back into his role as a managing partner of ARCHIMED, the healthcare-focused global private equity firm that holds a majority stake in NAMSA.Ballester led the search for a new CEO and notes: "Brian is globally recognized as a respected healthcare executive, having served in various leadership roles over the past 15 years as a Board Member, Operating Partner, Chairman of the Board, and Chief Executive Officer with extensive experience in operational, commercial, and innovation strategies. Brian's international experience, having lived and worked in Hong Kong, Shanghai, and Singapore, will be invaluable as we continue to expand our global footprint."Smith adds: "I am thrilled to join an organization with the history, reputation, and contribution to improved patient outcomes that NAMSA has repeatedly demonstrated for decades. I look forward to making my own contribution to this ongoing success story."NAMSA recently announced that it had signed a definitive agreement to purchase the US medical device testing operations of WuXi AppTec

BioSpace
Jan 17th, 2025
NAMSA Acquires the U.S. Medical Device Testing Operations of WuXi AppTec, Solidifying its Position as the Leader in MedTech Testing and Clinical Research

Under the agreement, NAMSA will acquire WuXi AppTec facilities in Minnesota and Georgia.

BioSpectrum Asia
Oct 16th, 2024
Japanese med tech leader Terumo announces strategic outsourcing partnership with Namsa

Japanese med tech leader Terumo announces strategic outsourcing partnership with Namsa.

Google
Jul 18th, 2023
NAMSA acquires german based CRI to expand clinical research and geographic reach across europe | business wire

NAMSA acquires german based CRI to expand clinical research and geographic reach across europe | business wire.